News from csl behring A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 09, 2016, 09:00 ET CSL Behring Awards LEAD Grants to Help Rare Disease Patient Groups Achieve Their Advocacy Objectives

Patients are their own most important advocates, and global biotherapeutics leader CSL Behring has renewed its commitment to helping empower them...


Mar 04, 2016, 08:13 ET U.S. FDA Approves CSL Behring's IDELVION® -- The First and Only Hemophilia B Therapy with Up to 14-day Dosing Intervals

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved IDELVION® [Coagulation Factor IX (Recombinant), Albumin...


Feb 23, 2016, 09:30 ET First Export of Privigen® From New Manufacturing Facility in Broadmeadows, Melbourne, Australia

Global biotherapeutics leader CSL Behring today announced an increase in the global supply of Privigen® as the first export has been shipped from a...


Feb 02, 2016, 08:00 ET CSL Behring and Its Employees Pass $1 Million Mark in Charitable Donations to Communities Throughout the U.S.

CSL Behring's U.S. locations in King of Prussia and Kankakee, Il., and its subsidiary, CSL Plasma headquartered in Boca Raton, Fla., raised more than ...


Dec 22, 2015, 09:00 ET CSL Behring Submits Marketing Authorization Application to the European Medicines Agency for rVIII-SingleChain for Patients with Hemophilia A

Global biotherapeutics leader CSL Behring announced today that the company has submitted its Marketing Authorization Application (MAA) to the...


Dec 21, 2015, 09:01 ET CSL Behring Submits New Drug Application to Japan's Pharmaceuticals and Medical Devices Agency for rIX-FP for Hemophilia B Patients

Global biotherapeutics leader CSL Behring announced today that the company has submitted its new drug application to Japan's Pharmaceuticals and...


Dec 10, 2015, 10:28 ET CSL Behring expandiert Geschäftsaktivitäten in Russland

Der globale Marktführer für Biotherapeutika CSL Behring gab heute seine jüngste geografische Expansion bekannt, um mehr Patienten einen besseren...


Dec 10, 2015, 09:42 ET CSL Behring ekspanduje do Rosji

Największy światowy producent środków bioterapeutycznych, CSL Behring, ogłosił dzisiaj swoją najnowszą ekspansję geograficzną zmierzającą do...


Dec 10, 2015, 09:22 ET CSL Behring expanduje do Ruska

CSL Behring, globální společnost s vedoucím postavením mezi výrobci bioterapeutik, dnes oznámila rozšíření své geografické působnosti a zahájení...


Dec 10, 2015, 07:27 ET CSL Behring начинает деятельность в России

Мировой лидер в сфере биотерапии – компания CSL Behring, - сегодня сообщила о новом шаге на пути к географическому расширению своего присутствия с...


Dec 10, 2015, 06:41 ET CSL Behring rozširuje prevádzky do Ruska

Popredná globálna bioterapeutická spoločnosť CSL Behring dnes oznámila otvorenie novej pobočky v Rusku, aby zabezpečila prístup k liečbe pre väčší...


Dec 10, 2015, 03:00 ET CSL Behring expande sus operaciones a Rusia

El líder terapéutico global CSL Behring ha anunciado hoy su última expansión geográfica para ofrecer a más pacientes mayor acceso al tratamiento...


Dec 10, 2015, 01:31 ET CSL Behring étend ses opérations en Russie

Le leader mondial de biothérapeutiques CSL Behring a annoncé aujourd'hui sa plus récente expansion géographique afin de fournir à davantage de...


Dec 08, 2015, 08:00 ET CSL Behring Expands Operations to Russia

Global biotherapeutics leader CSL Behring announced today its latest geographic expansion to provide more patients with greater access to treatment...


Dec 07, 2015, 11:00 ET CSL Behring Presents Phase III Data for Its Long-Acting Recombinant Factor IX Albumin Fusion Protein for Hemophilia B at the 57th ASH Annual Meeting & Exposition

Global biotherapeutics leader CSL Behring today presented data from its Phase III PROLONG-9FP clinical program evaluating the efficacy and long-term...


Dec 02, 2015, 09:00 ET CSL Behring to Present New Data for rIX-FP and rVIII-SingleChain at the 57th ASH Annual Meeting & Exposition

CSL Behring announced today that it will present several abstracts from its recombinant coagulation factor development programs at the American...


Sep 08, 2015, 10:00 ET Centers for Medicare and Medicaid Services Extends New Technology Add-On Payment for CSL Behring's Kcentra® for Third Year

CSL Behring today announced that the Centers for Medicare and Medicaid Services (CMS) again extended the new technology add-on payment (NTAP) for...


Aug 25, 2015, 09:01 ET CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors

CSL Behring announced today that the first patient has been enrolled in its Phase II/III clinical study evaluating the pharmacokinetics (PK),...


Jul 28, 2015, 09:01 ET Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B

CSL Behring announced today that Swissmedic has accepted for review a Marketing Authorization Application (MAA) for the company's investigational...


Jul 28, 2015, 09:00 ET U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A

CSL Behring announced today that the U.S. Food and Drug Administration has accepted for review the company's Biologics License Application (BLA) for...


Jun 29, 2015, 01:30 ET CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient

CSL Behring announced today that Mohammad Alsharabati, MD, University of Alabama at Birmingham, United States, is the recipient of the 2015...


Jun 24, 2015, 08:31 ET CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A

CSL Behring today presented data from a Phase I/III study on the efficacy and safety of its novel investigational recombinant factor VIII single...


Jun 24, 2015, 05:16 ET CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015

CSL Behring today presented data from Phase III studies evaluating the efficacy and long-term safety of its investigational long-acting fusion...


Jun 17, 2015, 12:15 ET Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers

The cost of medicines in general and biopharmaceutical therapies used to treat rare diseases in particular has faced increased attention from payers...


Jun 16, 2015, 09:00 ET CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress

CSL Behring announced today it will present more than 20 abstracts, including five oral presentations, from across its hematology portfolio of...